Ferring Pharmaceuticals INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$12Mgeneral payments (2019-2025)
$40Kresearch payments (2019-2025)
31,769clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Adstiladrin $2.4M associated (2023-2025)
- Rebyota $2.1M associated (2023-2025)
- Menopur $1.5M associated (2023-2025)
- Euflexxa $320K associated (2023-2025)
- Clenpiq $23K associated (2023-2025)
- Cimzia $15K associated (2023-2025)
- Endometrin $4,588 associated (2023-2025)
- Cervidil $2,410 associated (2023-2025)
- Firmagon $930 associated (2023-2025)
- Fyremadel $83.28 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Grannum Sant | Bridgewater, NJ | Urology | $472,172.12 |
| Paul Feuerstadt | Hamden, CT | Gastroenterology (Internal Medicine) | $399,136.52 |
| Fady Sharara | Reston, VA | Reproductive Endocrinology | $229,597.98 |
| John Park | Raleigh, NC | Reproductive Endocrinology | $154,617.36 |
| Carl Crawford | New York, NY | Gastroenterology (Internal Medicine) | $148,638.37 |
| Jason Griffith | Spring, TX | Reproductive Endocrinology | $144,577.57 |
| Gautam Jayram | Nashville, TN | Urology | $138,215.06 |
| Ravi Chauhan | Germantown, TN | Urology | $124,281.89 |
| Michael Scheiber | Cincinnati, OH | Reproductive Endocrinology | $118,583.66 |
| Anurag Maheshwari | Baltimore, MD | Gastroenterology (Internal Medicine) | $115,131.60 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.